ROS / pH dual-response modified seventeen-type collagen microneedle patch loaded with bioactive substances and application of ROS / pH dual-response modified seventeen-type collagen microneedle patch
Through ROS/pH double-response modified Seventeen collagen microneedle patch, IGF-1 is accurately released in androgenic hair loss areas, solving the side effects and unstable efficacy of traditional treatment methods, and achieving low-cost and no Painful hair follicle regeneration and growth effects.
Patent Information
- Application Number
- CN202411149515.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-21
AI Technical Summary
The existing androgenic hair loss treatment methods have side effects, unstable efficacy and high cost, especially since drug treatment requires long-term compliance and laser treatment costs, and traditional microneedle technology is difficult to ensure the precise release of drugs under appropriate conditions. The release rate and amount cannot meet the treatment needs.
Using ROS/pH double-response modified Seventeen collagen microneedle patch, the bioactive substance IGF-1 is combined with boric acid modified Seventeen collagen hydrogel, and the physically inert polymer PVA is used to make degradable micro-microsine The needle patch uses ROS/pH biresponsive borate bond to break in the surrounding environment of the hair follicle to achieve the precise release of IGF-1.
It realizes painless and minimally invasive delivery of IGF-1 to hair follicle stem cells, promotes hair follicle regeneration and growth, reduces treatment side effects, is low-cost and has a sustained release effect, significantly improving the therapeutic effect.
Smart Images

Figure CN119015206A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomaterials, and in particular to a ROS / pH dual-responsive modified type XVII collagen microneedle patch loaded with bioactive substances and applications thereof. Background Art
[0002] Alopecia is becoming a global public concern. It is a hair disease characterized by the gradual miniaturization of hair follicles and a shortened growth period, resulting in a decrease in scalp hair. Although hair loss does not affect physical health, it can have a negative impact on patients' mental health and lead to a decreased quality of life. Early diagnosis and treatment can significantly slow the progression of hair loss and improve prognosis. Treatment includes medications such as minoxidil and finasteride, which require long-term patient compliance but have varying efficacy. Common side effects include sexual dysfunction, depressive mood changes, and skin irritation. The effectiveness of the surgery is affected by the surgeon's proficiency and is only suitable for patients with sufficient donor hair. In addition, unnatural hairlines and scars in the donor area are also frequently reported problems. In addition to genetic factors, the onset of androgenic alopecia may also be affected by other factors, such as environmental factors, changes in hormone levels, health status, etc.
[0003] Traditional treatments for androgenic alopecia mainly include oral medications, topical medications, and laser therapy. However, these treatments have some limitations, such as oral medications may cause side effects, topical medications need to be used frequently and have limited effects, and laser treatments are expensive and require periodic treatments. The emergence of microneedle technology has brought new ideas to the treatment of hair loss. Microneedle therapy uses tiny needle tips to puncture the skin surface, stimulate the skin's self-repair mechanism, and promote skin regeneration and hair follicle growth.
[0004] During androgenic alopecia, the level of oxidative stress around the hair follicles usually increases, leading to increased cellular oxidative damage and accelerated hair follicle decline. At the same time, the pH value around the hair follicles may also change. Androgenic alopecia may cause changes in the pH of the tissue around the hair follicles. At this time, the advantages of environmentally responsive microneedles over ordinary microneedles are reflected. Environmentally responsive microneedles are an innovative microneedle technology that adds environmentally responsive materials to ordinary microneedles. It can automatically release active ingredients according to environmental conditions and has a more precise and efficient therapeutic effect. Environmentally responsive microneedles may contain some ROS-sensitive drug carriers, such as compounds containing disulfide bonds. These drug carriers will release antioxidant or anti-inflammatory drugs when they detect elevated ROS levels. At the same time, environmentally responsive microneedles may contain pH-sensitive drug carriers, such as compounds containing acidic or basic groups. When these drug carriers detect abnormal pH values, they will release drugs, such as growth factors, anti-inflammatory drugs, etc., which help regulate the acid-base balance of the environment around the hair follicles and promote hair follicle regeneration and growth. However, how to ensure that the drugs in the microneedle patch are released under appropriate conditions and that the release rate and amount can meet the treatment needs is one of the technical problems that need to be solved. Summary of the invention
[0005] The purpose of the present invention is to provide a ROS / pH dual-responsive modified type XVII collagen microneedle patch loaded with bioactive substances and its application, and to develop a degradable microneedle patch made of a physically inert polymer PVA by combining the bioactive substances with modified collagen hydrogel, which can deliver the bioactive substances to the hair follicle stem cells in the area of androgenic alopecia.
[0006] In order to achieve the above object, the present invention adopts the following technical solution:
[0007] The microneedle patch provided by the present invention is composed of ROS / pH dual-responsive boric acid-modified type 17 collagen gel
[0008] @IGF-1 and polymer matrix composition;
[0009] The polymer substrate is composed of PVA, a physically inert polymer with good biocompatibility. The preparation method thereof is as follows: 4 g of PVA is dissolved in 20 ml of deionized water to prepare a 20% PVA solution, which is stored at room temperature for later use.
[0010] ROS / pH dual-responsive modified type 17 collagen is formed by reacting type 17 collagen with 3-amino-4-methoxybenzoic acid (AMB) by oxidative polymerization, and then cross-linking with 3-aminophenylboronic acid (ABA) under the action of a cross-linking agent such as 2-morpholineethanesulfonic acid (MES). The specific steps are as follows:
[0011] First, 1 g of type 17 collagen and 100 mg of 3-amino-4-methoxybenzoic acid were dissolved in 20 ml of deionized water, and 136.5 mg of ammonium persulfate (APS) was added as an oxidative polymerization catalyst. After 24 h, the reaction solution was dialyzed in deionized water for at least 3 days (Mw=3500), and then freeze-dried to obtain Col17-AMB.
[0012] Secondly, 1g of modified type 17 collagen Col17-AMB was taken out from the freeze-dried sample and dissolved in 2-morpholineethanesulfonic acid (MES, 20ml, pH=5.0) buffer. At the same time, 0.26g of 3-aminophenylboronic acid, 0.16g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl), and 0.06g of N-hydroxysuccinimide (NHS) were fully dissolved in the buffer and stirred in an ice bath for 2h. After 2h, it was added to the collagen solution and stirred for 48h. The boric acid-modified type 17 collagen was obtained by dialysis and freeze-drying.
[0013] The collagen hydrogel uses boric acid-modified type 17 collagen and polyvinyl alcohol (PVA) to form a gel by physical and chemical double crosslinking. The 3-aminophenylboronic acid in the boric acid-modified type 17 collagen is chemically crosslinked with PVA to form a dynamic borate ester bond to form a gel. The physical property of PVA repeated freeze-thaw gelation is then used to synthesize the boric acid-modified type 17 collagen hydrogel. Taking 5% boric acid-modified type 17 collagen hydrogel as an example: 50 mg of boric acid-modified type 17 collagen is weighed and added with 1 ml of deionized water to dissolve, and then 100 mg of polyvinyl alcohol (PVA) is weighed and added with 1 ml of deionized water to dissolve. The two solutions are mixed and ultrasonicated for 1 min, then placed in a -20°C refrigerator and frozen for 6 h, then taken out, placed at room temperature to thaw for 3 h, and repeatedly frozen and thawed several times to obtain a 5% boric acid-modified type 17 collagen hydrogel.
[0014] The encapsulation method of the bioactive substance IGF-1 is as follows: 200 mg of freeze-dried boric acid-modified type 17 collagen hydrogel is immersed in 10 mL of PBS, and then 65 ul of 1 mg / ml IGF-1 solution from GenScript is added, and then immersed for 3 days to allow the freeze-dried gel to reach drug loading equilibrium.
[0015] The present invention also provides a method for preparing the above-mentioned microneedle patch, which is specifically:
[0016] First, 50 mg of the drug-loaded boric acid-modified type 17 collagen hydrogel was placed on the microneedle PDMS mold, and a small medicine spoon was used to press the drug-loaded boric acid-modified type 17 collagen hydrogel into the pinhole of the mold. The mold was centrifuged at 2200 rpm for 15 minutes, and then the pressed mold was placed in a vacuum drying oven and repeatedly vacuumed three times.
[0017] Secondly, 20% PVA solution was cast onto the mold carrying the microneedle patch, and finally the covered mold was placed in a ventilated place to dry for one day, the microneedle patch was carefully peeled off, and the resulting microneedle patch was stored in a sealed well plate for further study.
[0018] The ROS / pH dual-responsive collagen microneedle patch loaded with bioactive substances of the present invention is composed of boric acid-modified type XVII collagen hydrogel @IGF-1 and a polymer matrix. When applied to the skin, the microneedle tip reaches the area where hair follicle stem cells exist in a painless and minimally invasive manner. Due to the presence of reactive oxygen in the environment and the influence of the skin pH environment, the borate ester bond in the collagen hydrogel is broken, thereby removing reactive oxygen and releasing the encapsulated IGF-1 into the hair follicle stem cells. Compared with the traditional androgenic alopecia treatment drug minoxidil, the collagen microneedle patch with ROS / pH dual response provides an effective potential treatment for androgenic alopecia.
[0019] Compared with other treatment methods, the present invention has the following beneficial effects:
[0020] (1) The ROS / pH dual-responsive collagen hydrogel@IGF-1 contained in the present invention is formed by borate bonds. The borate bonds are broken when they encounter reactive oxygen species (ROS) in the environment and the influence of the skin pH environment, thereby removing the reactive oxygen species and releasing the encapsulated IGF-1 into the hair follicle stem cells.
[0021] (2) The microneedle patch of the present invention is simple to prepare and has low cost, which lays a foundation for large-scale preparation.
[0022] (3) The microneedle material contains IGF-1 and collagen, which stimulate cell proliferation and differentiation and promote the activation and growth of hair follicles. The microneedle patch made of collagen hydrogel has a certain sustained release effect and is slowly released in the body for several days after use. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 These are bright field images of boric acid-modified type XVII collagen hydrogel before and after gelation.
[0024] Figure 2 The hydrogel was tested for injectability by syringe.
[0025] Figure 3 The rheological properties of type XVII collagen hydrogels modified with boric acid in different proportions.
[0026] Figure 4 This is the nuclear magnetic resonance detection spectrum of type 17 collagen and boric acid-modified type 17 collagen.
[0027] Figure 5It is the FITR detection spectrum of type 17 collagen, AMB-modified type 17 collagen, and boric acid-modified type 17 collagen.
[0028] Figure 6 The antioxidant capacity of type XVII collagen hydrogel modified with boric acid in different ratios.
[0029] Figure 7 The in vitro release of boric acid modified type XVII collagen in four different environments.
[0030] Figure 8 The in vivo release of boric acid-modified type XVII collagen after microneedling on the back of mice.
[0031] Fig. 9 This is an ultra-depth-of-field microscopy image of boric acid-modified type XVII collagen microneedles.
[0032] Fig.10 This is the SEM image of boric acid-modified type 17 collagen microneedles.
[0033] Fig.11 In vitro degradation of boric acid-modified type XVII collagen microneedles after pressing on 6% agarose.
[0034] Fig.12 In vivo degradation of boric acid-modified type XVII collagen microneedles after back pressing on mice.
[0035] Fig.13 Animal experiments.
[0036] Fig.14 H&E staining results of mouse dorsal skin.
[0037] Fig.15 Immunofluorescence results of mouse back skin.
[0038] Fig.16 Biocompatibility test results.
[0039] Fig.17 Results of cell migration assay.
[0040] Fig.18 This is a diagram showing the preparation and use process of the microneedle patch of the present invention. DETAILED DESCRIPTION
[0041] The technical scheme of the present invention is further explained below in conjunction with the examples. Those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be regarded as limiting the scope of the present invention. If no specific conditions are specified in the examples, the conditions are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.
[0042] Example 1 Preparation of boric acid modified type 17 collagen
[0043] First, 1 g of type 17 collagen and 100 mg of 3-amino-4-methoxybenzoic acid were dissolved in 20 ml of deionized water, and 136.5 mg of ammonium persulfate (APS) was added as an oxidative polymerization catalyst. After 24 h, the reaction solution was dialyzed in deionized water for at least 3 days (Mw=3500, and then freeze-dried to obtain modified type 17 collagen Col17-AMB.
[0044] Secondly, take out 1g of modified type 17 collagen from the freeze-dried sample and dissolve it in 2-morpholineethanesulfonic acid (MES, 20ml, pH=5.0) buffer. At the same time, fully dissolve 3-aminophenylboronic acid (ABA, 0.26g), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC·HCl, 0.16g), and N-hydroxysuccinimide (NHS, 0.06g) in 20ml, pH=5.0 MES buffer and stir in an ice bath for 2h. After 2h, add it to the collagen solution and stir for 48h. Dialyze and freeze-dry to obtain boric acid-modified type 17 collagen, namely Col17-BA.
[0045] Example 2 Preparation of boric acid modified type 17 collagen hydrogel
[0046] Weigh 50 mg of boric acid-modified type 17 collagen and add 1 ml of deionized water to dissolve it. Then weigh 100 mg of polyvinyl alcohol (PVA) and add 1 ml of water to dissolve it. Mix the two solutions and put them in a -20°C refrigerator to freeze for 6 hours, then take them out and thaw them at room temperature for 3 hours. Repeat the freezing and thawing several times to obtain boric acid-modified type 17 collagen hydrogel.
[0047] Example 3 Encapsulation of the biologically active substance IGF-1
[0048] 200 mg of freeze-dried boric acid-modified type XVII collagen hydrogel was soaked in 10 mL of PBS, and then 65 μl of 1 mg / ml IGF-1 solution from GenScript was added. The freeze-dried gel was soaked for 3 days to allow the freeze-dried gel to reach drug loading equilibrium, thereby obtaining drug-loaded boric acid-modified type XVII collagen hydrogel.
[0049] Example 4 Preparation of ROS / pH Dual-Response Collagen Microneedle Patch
[0050] Take 50 mg of drug-loaded boric acid-modified type 17 collagen hydrogel and place it on the microneedle PDMS mold. Use a small medicine spoon to press the gel into the pinhole of the mold as the microneedle tip, and centrifuge the mold at 2200 rpm for 15 minutes; then put the pressed mold into a vacuum drying oven and repeatedly evacuate it three times; secondly, pour 20% PVA solution onto the PDMS mold carrying the needle until it completely covers the needle and just fills the mold, with a thickness of about 0.5 ml. Finally, place the covered mold in a ventilated place to dry for one day, carefully peel off the microneedle patch, and store the resulting microneedle patch in a sealed well plate for further study.
[0051] Example 5 Determination of Antioxidant Capacity of Modified Type XVII Collagen Hydrogel
[0052] Prepare boric acid modified type 17 collagen hydrogels with Wt% of 2.5%, 5%, and 7.5% respectively (i.e., for example, 2.5% boric acid modified type 17 collagen hydrogel is 25 mg boric acid modified type 17 collagen added with 1 ml deionized water and then mixed with 1 ml 10% PVA solution; 5% boric acid modified type 17 collagen hydrogel is: weigh 50 mg boric acid modified type 17 collagen, add 1 ml deionized water to dissolve, and then mix with 1 ml 10% PVA solution). Weigh 3 50 mg hydrogels each and place them in 9 5 ml centrifuge tubes in total, and then use the DPPH kit of Shanghai Yuanye Biotechnology Co., Ltd. to test the antioxidant capacity of the hydrogels.
[0053] Example 6 In vitro degradation ability of microneedle patch
[0054] Weigh 3g of agarose in a 50ml beaker and add 50ml of deionized water to make a 6% agarose solution. Then heat the agarose solution in a microwave oven until it boils, repeat three times, pour it into the cell culture dish, and put it in a 4℃ refrigerator for one hour to freeze and solidify. Use inverted fluorescence to photograph the needle tip morphology of the microneedle patch at 0min in the bright field, place the microneedle on the 6% agarose, press with a 1kg weight and time for 1min, then photograph the degradation of the microneedle for 1min, and finally take a photo of the microneedle patch completely degraded in the fourth minute.
[0055] Example 7 In vitro degradation ability of microneedle patch
[0056] After the boric acid-modified type XVII collagen microneedles were pressed on the back of mice for 5, 10, 15, and 20 minutes, the needle tip morphology was photographed in the bright field using inverted fluorescence.
[0057] Example 8 In vitro release capacity
[0058] The boric acid-modified type 17 collagen hydrogel containing rhodamine B-stained bovine serum albumin (BSA) was placed in a 15ml centrifuge tube to simulate the release of IGF-1. The centrifuge tube was divided into four groups, and 10ml of 0.2mM H2O2+pH7.4PBS solution, 0.2mM H2O2+pH 5PBS solution, pH 7.4PBS solution, and pH 5PBS solution were added respectively. The centrifuge tube was placed in a shaker at 37°C, and 1ml of sample was taken at intervals and supplemented with the same 1ml solution. After 24h, it was added to a 96-well plate and photographed with a live imaging instrument.
[0059] Example 9 In vivo release capacity
[0060] After the rhodamine B-stained boric acid-modified type XVII collagen microneedles were pressed on the back of mice for 20 minutes, the release was imaged in an in vivo imager every day.
[0061] Example 10 Hair follicle regeneration experiment
[0062] The specific experimental steps are:
[0063] (1) Mouse model of androgenic alopecia
[0064] Twenty-four male 6-week-old C57BL / 6 mice were injected subcutaneously with testosterone solution (0.2%, w / v, 0.1 mL / cm 2 ) for 35 consecutive days to induce the AGA model; during the entire experimental period (35 days), each animal was injected with 0.2 mL of 0.2% testosterone solution every day. On the 14th day after injection, the hair on the back skin was removed by shaving an area of 2×3 cm. The mice were randomly divided into 4 groups: ① PBS group ② Minoxidil group ③ COL17-BA MNs group ④ IGF-1@COL17-BA MNs group. After modeling, the skin of the mice turned pink and thickened, indicating that the modeling was successful.
[0065] (2) Animal grouping
[0066] On day 14 after injection, hair on the back skin was removed by shaving a 2 × 3 cm area. The mice were randomly divided into 4 groups:
[0067] ①PBS group, 200 μl PBS, applied on the back
[0068] ② Minoxidil group: 200 μl minoxidil was applied on the back.
[0069] ③COL17-BA MNs group, back pressing for 15 minutes.
[0070] ④IGF-1@COL17-BA MNs group, back pressing for 15 minutes.
[0071] (3) On the 14th day after androgen modeling, a 2×3 cm area was shaved to remove the hair on the back skin, and medication was started on the 14th day, with an interval of two days. On the 15th day, photos were taken to record the hair growth on the back of the mice, with an interval of five days.
[0072] After observation, as time goes by after the drug administration, the skin of the IGF group first turns blue and shows a tendency to grow hair on the 11th day after the start of drug administration, followed by the minoxidil group and the blank microneedle group on the 16th day. Meanwhile, the PBS group also has a little hair growth. The results are shown in the attached figure, and it can be seen that the speed of promoting hair follicle regeneration using the drug-loaded microneedle patch of the present invention is significantly greater than that of the control group.
[0073] Example 11 Biocompatibility Experiment
[0074] The MTT method was used to investigate the toxicity of boric acid-modified type 17 collagen to L929 cells, in order to evaluate the biocompatibility of boric acid-modified type 17 collagen. First, cells were seeded in 96-well microplates (10 cells per well). 4 The boric acid-modified type 17 collagen hydrogel (2 g) and the boric acid-modified type 17 collagen (2 g) loaded with IGF were added to 2 ml of DMEM culture medium for extraction overnight, and then the two extracts were co-incubated with the cells cultured overnight. After incubation for 24 hours, the cell viability was evaluated by measuring the absorbance at 490 nm with an ELISA reader to evaluate the biocompatibility of the boric acid-modified type 17 collagen. The results are shown in the attached Fig.16 The results showed that boric acid-modified type XVII collagen would not be toxic to cells.
[0075] Example 12 Cell migration experiment
[0076] First, draw three horizontal lines on the bottom of the six-well plate with a marker pen and a ruler as marking lines. Then divide the plate into three groups: Control, COL17-BA, and IGF@COL17-BA. Add 2 ml of the prepared cell suspension to each well, with a cell density of 6x10 6 About 100 cells / well, and spread them evenly. After the cells are fully grown, use a ruler to compare, and use the 200ul gun tip to draw two vertical lines perpendicular to the well plate and the marked line, so that the scratches intersect with the marked lines, and several intersections can be formed as fixed detection points. Then discard the old culture medium and gently rinse with PBS two to three times until the scratched cells are rinsed clean. Add drug-added culture medium or serum-free culture medium according to the grouping. After scratching, washing, and adding liquid, take photos of different magnifications with a microscope as a 0h control. Culture in a 37℃, 5% CO2 incubator. Take out the cells at the required time point, observe the width of the scratches at the same position under a microscope and take pictures. Finally, use ImageJ software to analyze the migration area.
[0077] Based on the above ideal embodiments of the present invention, the relevant staff can make various changes and modifications without departing from the technical concept of the present invention through the above description. The technical scope of the present invention is not limited to the contents of the specification, and its technical scope must be determined according to the scope of the claims.
Claims
1. A ROS / pH dual-responsive modified type 17 collagen microneedle patch loaded with bioactive substances, characterized in that: The microneedle patch is composed of bioactive substances, boric acid-modified type 17 collagen and a polymer matrix polyvinyl alcohol.
2. The ROS / pH dual-responsive modified type 17 collagen microneedle patch loaded with bioactive substances according to claim 1, characterized in that: The boric acid-modified type 17 collagen is formed by reacting type 17 collagen with 3-amino-4-methoxybenzoic acid AMB by oxidative polymerization, and then cross-linking with 3-aminophenylboronic acid ABA under the action of 2-morpholineethanesulfonic acid MES cross-linking agent.
3. The ROS / pH dual-responsive modified type 17 collagen microneedle patch loaded with bioactive substances according to claim 1, characterized in that: The preparation method of the polymer matrix is as follows: polyvinyl alcohol is dissolved in deionized water to prepare a 20% PVA solution, which is stored at room temperature for later use.
4. The ROS / pH dual-responsive modified type 17 collagen microneedle patch loaded with bioactive substances according to claim 1, characterized in that: The biologically active substance is insulin-like growth factor IGF-1.
5. A method for preparing the ROS / pH dual-responsive modified type 17 collagen microneedle patch loaded with bioactive substances according to claim 1, characterized in that: The specific steps of the preparation method of the microneedle patch are as follows: (1) Weighing boric acid-modified type 17 collagen and adding deionized water to dissolve it, then weighing polyvinyl alcohol and adding deionized water to dissolve it, mixing the two solutions for 1 minute, placing them in a -20°C refrigerator for 6 hours, then taking them out and thawing them at room temperature for 3 hours, and repeatedly freezing and thawing to obtain boric acid-modified type 17 collagen hydrogel; (2) Soaking the boric acid-modified type XVII collagen hydrogel in PBS, then adding IGF-1 solution, and soaking for 3 days to allow the freeze-dried gel to reach drug loading equilibrium; (3) placing the drug-loaded boric acid-modified type 17 collagen hydrogel on the microneedle PDMS mold, using a small medicine spoon to press the drug-loaded boric acid-modified type 17 collagen hydrogel into the pinhole of the mold as the microneedle tip, and centrifuging the mold at 2200 rpm for 15 minutes; then placing the pressed mold in a vacuum drying oven and repeatedly evacuating it three times; (4) Pour 20% PVA solution onto the mold carrying the microneedle patch, and finally place the covered mold in a ventilated place to dry for one day, and then peel off the microneedle patch.
6. An application of the ROS / pH dual-responsive modified type 17 collagen microneedle patch loaded with bioactive substances according to claim 1, characterized in that: The ROS / pH dual-responsive modified type 17 collagen microneedle patch loaded with bioactive substances is used for preparing a patch for androgen-induced hair loss.
Citation Information
Patent Citations
Medical hydrogel with pH sensitivity, self-healing nature and cell adhesion and preparation method thereof
CN108530651A
Double-layer intelligent microneedle patch co-loaded with nano-enzyme and ICB antibody and preparation method of double-layer intelligent microneedle patch
CN116570828A
Anti-hair loss essence containing recombinant human XVII collagen and preparation method thereof
CN118388631A
Core-shell microneedle patch for h2o2 and ph cascade-triggered insulin delivery
US20210186865A1
